
Opinion|Videos|December 9, 2024
Closing Thoughts and Unmet Needs in Glioma Treatment
Author(s)Vinay K. Puduvalli, MD
Panelists discuss how unmet needs in glioma treatment persist despite recent advances, highlighting key areas for future research and development to improve outcomes and quality of life for patients with gliomas.
Advertisement
Episodes in this series

Advertisement
Related to this article

“This is the closest we have been to biomarkers replacing ultrasound,” said Amit G. Singal, MD, MS, FAASLD.

ADCs directed towards B7-H3, SEZ, DLL3, and TROP2 appear to be “super exciting,” according to Anne Chiang, MD, PhD.

Neoadjuvant eftilagimod alfa, pembrolizumab, and radiotherapy produced an 81.1% 12-month DFS rate in high-risk, resectable soft tissue sarcoma.

Rezatapopt monotherapy yielded an ORR of 48% in TP53 Y220C-mutated platinum-resistant/refractory ovarian cancer.

Anne Chiang, MD, PhD, discusses DeLLphi-305 and other leaps forward in small cell lung cancer, along with a setback regarding lurbinectedin.

The FDA granted RMAT designation to inzitagene plasmivec for advanced melanoma ahead of a phase 3 trial expected to start in December 2026.

Variation in the mitochondrial genome carries prognostic information about graft-versus-host disease that current clinical risk scores do not capture.
Advertisement
Advertisement
Trending on CancerNetwork
1
Rethinking HCC Surveillance and Treatment Amid a Shifting Risk Landscape
2
Sequencing B7-H3 and SEZ6 ADCs With DLL3 Bispecifics in SCLC
3
Testosterone Therapy Shows No Added Progression Risk in Active Surveillance PCa
4
Efti Plus Pembrolizumab and RT Yields 81% 12-Month DFS in Soft Tissue Sarcoma
5

